Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02933944
Recruitment Status : Terminated (Changing priorities)
First Posted : October 14, 2016
Last Update Posted : June 14, 2019
Sponsor:
Information provided by (Responsible Party):
Targovax ASA

Brief Summary:

The purpose of this study is to determine safety and anti-tumor immune activation generated by TG02 and Granulocyte macrophage colony stimulating factor (GM-CSF), first as monotherapy (Part I), thereafter in combination with the checkpoint inhibitor pembrolizumab (Part II), in patients with locally advanced primary and recurrent colorectal cancer scheduled to have surgery.

Part I will include 4-6 patients and Part II will include up to 10 patients. Part I and Part II are separate and independent sequential components of the study. Patients will only be able to participate in either the Part I cohort or Part II cohort.

Main objective of the study is to investigate safety and immune response after TG02-treatment.


Condition or disease Intervention/treatment Phase
Rectal Cancer Biological: TG02-treatment Drug: Pembrolizumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
Study Start Date : September 2016
Actual Primary Completion Date : February 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TG02-treatment

Part I: The TG02-treatment consists of an intradermal injection of GM-CSF followed by an injection of TG02. The GM-CSF is to be given 15-30 minutes before TG02. TG02-treatment will be administered on Days 1, 8, 15, 22 and 36. If surgery after week 10, TG02-treatment will also be given at week 10 (Day 64).

Part II: TG02-treatment will be given as described under Part I. In addition pembrolizumab will be administered.

Biological: TG02-treatment
Drug: Pembrolizumab



Primary Outcome Measures :
  1. Safety of TG02-treatment by assessment of laboratory parameters (routine haematology and biochemistry), vital signs and recording of adverse events [ Time Frame: From start of study until End of study, which is approximately 4 weeks after surgery and maximum 20 weeks after start of TG02-treatment ]
  2. Number of patients with systemic TG02 specific immune response assessed by a Delayed Type Hypersensitivity (DTH) test. [ Time Frame: 8 weeks ]
  3. Systemic immune response assessed as change in presence of TG02 specific T-cells in peripheral blood [ Time Frame: 8 weeks ]
  4. Immunological activation in tumour mass by assessing number of patients with increased intra-tumoural lymphocytes. [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Change of immune suppression factors e.g. PD-1 and T-reg from pre to post treatment [ Time Frame: 8 weeks ]
  2. Change in pathological responses and markers of apoptosis in tumour tissue [ Time Frame: 8 weeks ]
  3. Changes in standard uptake values (SUV) will be assessed by FDG PET-CT images [ Time Frame: From screening until surgery ]
  4. Changes in the tumour marker Carcinoembryonic Antigen (CEA) throughout treatment will be assessed by analysis of blood samples to follow the evolution of disease under treatment [ Time Frame: From screening until surgery ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with locally advanced primary and recurrent colorectal cancer (CRC) (histologically or cytologically confirmed adenocarcinoma), with a confirmed oncogenic KRAS exon 2, codon 12 or 13 mutations, eligible for radical pelvic surgery at time of enrolment.
  • Patient is ≥18 years of age and able to consent
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
  • Patient has adequate organ and bone marrow function within 28 days of study

    • Neutrophil count >1.5 x10^9/L
    • Platelets >100 x10^9/L
    • Hb >90g/L
    • Total bilirubin <1.5 upper limit of normal, ULN
    • ALT and AST <3.0 x ULN
    • Serum creatinine <3 x ULN or Creatinine Clearance ≥ 30ml/min (Cockroft-Gault or Nuclear GFR method)
    • PT and APTT <1.3 x ULN
  • The patient is willing to provide study specific pre TG02-treatment biopsy of tumour mass and allow use of archival tumour biopsies. For patients where there are technical reasons a baseline biopsy cannot be performed but who fulfil all the other inclusion criteria, the investigator shall contact the medical monitor to discuss the possibility of including such patient.
  • The patient is willing and able to comply with the protocol, and agrees to return to the hospital for study visits and examinations
  • Men and women of childbearing potential must use adequate contraception to prevent pregnancy during the study. Adequate contraception is defined in the study as any medically recommended method (or combination of methods) as per standard of care. An adequate contraception includes hormonal contraception with implants or combined oral, transdermal or injectable contraceptives, certain intrauterine devices, bilateral tubal ligation, hysterectomy, or vasectomy of partner. A combination of male condom with either cap, diaphragm or sponge with spermicide are also considered acceptable. For women of childbearing potential a negative pregnancy test needs to be confirmed before inclusion.
  • The patient has been fully informed about the study and is willing to participate in the study, and has provided written informed consent form prior to any trial specific screening procedures.

Exclusion Criteria:

  • The patient has previously received an anticancer vaccine or immune checkpoint inhibitor, or participated in a trial involving the use of an anticancer vaccine or immune checkpoint inhibitor
  • Patients where pre-surgery radiotherapy, chemotherapy or other anti-cancer therapy has not been completed ≥ 2 weeks prior to TG02-treatment
  • The patients is receiving anti-cancer therapy for concurrent illness
  • The patient has had a prior different malignancy within the last 3 years (excluding adequately treated basal cell or squamous cell carcinoma of the skin cancer, or localised low grade tumours considered cured and not requiring systemic therapy)
  • The patient has uncontrolled or significant intercurrent or recent illness including:

    • auto-immune disorder or history of autoimmune disease requiring immunosuppressive treatment.
    • cardiac disorder such as uncontrolled cardiac failure, unstable angina or non-ST segment elevation myocardial infarction (NSTEMI) or myocardial infarction, uncontrolled arrhythmia less than 3 months before screening
    • stroke or thromboembolic event within 3 months of study commencement
    • active or uncontrolled severe infection
    • history of solid organ transplantation or any condition requiring chronic treatment with corticosteroids or other immunosuppressive agents
    • active coagulopathy/bleeding diathesis
    • cirrhosis, chronic active or untreated persistent hepatitis
    • history of adverse reactions to peptide vaccines
  • The patient is pregnant or lactating.
  • Has received an investigational drug within 4 weeks prior to study drug administration, or unless other has been agreed with the medical monitor
  • Is currently receiving any agent with a known effect on the immune system, unless at dose levels that are not immunosuppressive (e.g. prednisone at 10 mg/day or less or as inhaled steroid at doses used for the treatment of asthma)
  • Known history of positive tests for HIV/AIDS
  • Are planned to receive yellow fever or other live (attenuated) vaccines during the course of study
  • For Part II - any contraindication to receiving pembrolizumab:

If using the 50 mg lyophilized powder; hypersensitivity to the active substance (pembrolizumab) or to any of the excipients; L-histidine, L-histidine hydrochloride monohydrate, Sucrose, Polysorbate 80.

If using the 100 mg concentrate; hypersensitivity to the active substance (pembrolizumab) or to any of the excipients; L-histidine, Sucrose, Polysorbate 80


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02933944


Locations
Layout table for location information
Australia
Royal Brisbane & Women's Hospital (RBWH)
Brisbane, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
New Zealand
Auckland City Hospital
Auckland, New Zealand
Christchurch Hospital
Christchurch, New Zealand
Sponsors and Collaborators
Targovax ASA

Layout table for additonal information
Responsible Party: Targovax ASA
ClinicalTrials.gov Identifier: NCT02933944     History of Changes
Other Study ID Numbers: CT TG02-01
First Posted: October 14, 2016    Key Record Dates
Last Update Posted: June 14, 2019
Last Verified: June 2019

Keywords provided by Targovax ASA:
locally recurrent

Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents